Investigational drug · Phase 2
Envafolimab
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Biliary Tract Neoplasms, Solid Tumor, Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
101
Any phase or sponsor naming "Envafolimab"
First trial start
2021
Aug 6, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Envafolimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Biliary Tract Neoplasms
- Solid Tumor
- Solid Tumors
- Non-small Cell Lung Cancer
- Renal Cell Carcinoma
- Hepatocellular Carcinoma
- Advanced Endometrial Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Kidney cancer (renal cell carcinoma) · Liver cancer (hepatocellular carcinoma) · Endometrial cancer · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Envafolimab" as an intervention, largest first.
- The Effect of Serum Ferritin in irAERecruiting
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT06702566 · 1,500 participants (planned) · Start Jul 4, 2024 · Primary completion Jul 16, 2026
Drug: PD-1 and PD-L1 inhibitor; Targeted drugs and 1 more · For: Immune-related Adverse Event; Malignant Solid Tumors; Acute Leukemia and 1 more
Sites: Tianjin, China
The Second Affiliated Hospital of Chongqing Medical UniversityAcademic, hospital or other
NCT07852091 · 1,200 participants (planned) · Start Oct 10, 2023 · Primary completion Dec 31, 2026
Drug: Sintilimab/Envafolimab; ETV/TDF/TAF · For: Chronic Hepatitis B
Sites: Chongqing, China
- A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)Pivotal-lookingNot yet recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT06959693 · 590 participants (planned) · Start Jun 1, 2025 · Primary completion Sep 30, 2028
Drug: Cetuxima-β; Envafolimab and 1 more · For: Metastatic Colorectal Cancer (CRC)
Sites: Guangzhou, China
- Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTCPivotal-lookingCompleted
3D Medicines (Sichuan) Co., Ltd.Industry
NCT03478488 · 472 participants · Start Apr 16, 2018 · Primary completion Sep 10, 2024
Drug: KN035 plus Gemcitabine & oxaliplatin; Gemcitabine & oxaliplatin · For: Biliary Tract Neoplasms
Sites: Nanjing, China
- Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLCPivotal-lookingRecruiting
3D Medicines (Sichuan) Co., Ltd.Industry
NCT06123754 · 390 participants (planned) · Start Nov 17, 2023 · Primary completion Dec 30, 2027
Drug: Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection; placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection · For: Non-small Cell Lung Cancer
Sites: Tianjin, China
3D Medicines (Sichuan) Co., Ltd.Industry
NCT03101488 · 287 participants · Start Mar 21, 2017 · Primary completion Sep 2, 2019
Drug: KN035 · For: Solid Tumors
Sites: Changsha, China; Suzhou, China; Shanghai, China · 4 sites in all
Zhejiang UniversityAcademic, hospital or other
NCT06261138 · 279 participants · Start Feb 1, 2019 · Primary completion Mar 31, 2023
Drug: Transarterial chemoembolization · For: Hepatocellular Carcinoma
Sites: Hangzhou, China
- ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or MyxofibrosarcomaPivotal-lookingStatus unknown
Tracon Pharmaceuticals Inc.Industry
NCT04480502 · 207 participants · Start Dec 9, 2020 · Primary completion Oct 2024
Drug: Envafolimab; Ipilimumab · For: Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma
Sites: Tucson, Arizona; Los Angeles, California; Santa Monica, California · 30 sites in all
Peking University Shenzhen HospitalAcademic, hospital or other
NCT06692491 · 200 participants (planned) · Start Jan 1, 2025 · Primary completion Dec 31, 2027
Drug: Albumin-Bound Paclitaxel; Epirubicin and 26 more · For: Rare Tumour
- Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal CancerPivotal-lookingRecruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT05959356 · 198 participants (planned) · Start Nov 9, 2023 · Primary completion Dec 31, 2026
Drug: Cetuximab + Envafolimab + mFOLFOXIRI; Cetuximab + mFOLFOX6 · For: Metastatic Colorectal Cancer
Sites: Foshan, China; Guangzhou, China; Guiyang, China
Newest research
PubMed records naming it or its code names, newest first.
- Anlotinib plus envafolimab as neoadjuvant therapy in a patient with chemotherapy-refractory advanced endometrial cancer: A case report.
Xu J, Zhuang D, Wang L, et al. · Hum Vaccin Immunother 2026
- Case Report: From unresectable to resectable: successful conversion therapy with TACE, HAIC, envafolimab, and olaparib in advanced intrahepatic cholangiocarcinoma.
Ma C, Feng K, Zhou J · Front Oncol 2026
- Inhibited proliferation and immune evasion of lung cancer: The key role of miR-4483 in lncRNA linc00824/miR-4483/PD-L1 pathway.
Zhang JX, Qiu JM, Wang N, et al. · Biochem Biophys Res Commun 2026
- Immune checkpoint blockade and thrombo-inflammatory remodeling in microsatellite instability-high intrahepatic cholangiocarcinoma with Trousseau syndrome: a case report.
Sun X, Kuang X, Sun S, et al. · Front Med (Lausanne) 2026
- Complete clinical remission of squamous cell carcinoma of the root of the tongue following treatment with envafolimab in combination with neoadjuvant chemotherapy: A case report.
Xing L, Wang W, Liang H, et al. · J Cancer Res Ther 2026
- Dynamic Granulocyte Turnover Inferred From cfDNA Methylation Predicts Immunotherapy Benefit in Liver-Metastatic Small Cell Lung Cancer: A Prospective Biomarker Study.
Tang N, Shang X, Sun Y, et al. · MedComm (2020) 2026
Also in development for Biliary Tract Neoplasms
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.